Remedent, Inc. (REMI)
USD 0.05
(0.0%)
USD 0.05
(0.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 | -43.3 Thousand USD | 58.91% |
| 2023 | -105.4 Thousand USD | 39.36% |
| 2022 | -173.81 Thousand USD | -140.17% |
| 2021 | -72.37 Thousand USD | 33.71% |
| 2020 | -109.17 Thousand USD | -607.71% |
| 2019 | -15.42 Thousand USD | 62.46% |
| 2018 | -41.09 Thousand USD | 72.06% |
| 2017 | -147.1 Thousand USD | -106.91% |
| 2016 | 2.12 Million USD | 20.0% |
| 2015 | 1.77 Million USD | 1.03% |
| 2014 | 1.75 Million USD | -43.69% |
| 2013 | 3.11 Million USD | -2.33% |
| 2012 | 3.19 Million USD | 135.31% |
| 2011 | 1.35 Million USD | 93.08% |
| 2010 | 702.5 Thousand USD | 172.59% |
| 2009 | -967.73 Thousand USD | -21.69% |
| 2008 | -795.22 Thousand USD | -149.38% |
| 2007 | 1.61 Million USD | 268.58% |
| 2006 | 436.93 Thousand USD | 72.1% |
| 2005 | 253.88 Thousand USD | -40.95% |
| 2004 | 429.95 Thousand USD | 18.41% |
| 2003 | 363.11 Thousand USD | 101.14% |
| 2002 | -31.8 Million USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q4 | -43.3 Thousand USD | 36.41% |
| 2024 FY | -43.3 Thousand USD | 58.91% |
| 2024 Q3 | -68.09 Thousand USD | -85.47% |
| 2024 Q2 | -36.71 Thousand USD | 49.1% |
| 2024 Q1 | -72.13 Thousand USD | 31.56% |
| 2023 Q4 | -105.4 Thousand USD | -4.51% |
| 2023 Q1 | -169.38 Thousand USD | 0.0% |
| 2023 FY | -105.4 Thousand USD | 39.36% |
| 2023 Q2 | -135.82 Thousand USD | 19.82% |
| 2023 Q3 | -100.85 Thousand USD | 25.75% |
| 2022 FY | -173.81 Thousand USD | -140.17% |
| 2021 Q3 | -77.84 Thousand USD | 36.51% |
| 2021 FY | -72.37 Thousand USD | 33.71% |
| 2021 Q2 | -122.61 Thousand USD | -35.3% |
| 2021 Q1 | -90.61 Thousand USD | 17.0% |
| 2020 Q2 | 2024.00 USD | -72.27% |
| 2020 Q4 | -109.17 Thousand USD | -641.96% |
| 2020 FY | -109.17 Thousand USD | -607.71% |
| 2020 Q3 | -14.71 Thousand USD | -827.03% |
| 2020 Q1 | 7298.00 USD | 147.31% |
| 2019 FY | -15.42 Thousand USD | 62.46% |
| 2019 Q1 | -75.86 Thousand USD | 18.32% |
| 2019 Q2 | -55.11 Thousand USD | 27.34% |
| 2019 Q3 | -83.48 Thousand USD | -51.47% |
| 2019 Q4 | -15.42 Thousand USD | 81.52% |
| 2018 Q4 | -92.87 Thousand USD | -56.62% |
| 2018 Q3 | -59.29 Thousand USD | 33.23% |
| 2018 FY | -41.09 Thousand USD | 72.06% |
| 2018 Q2 | -88.81 Thousand USD | -32.23% |
| 2018 Q1 | -67.16 Thousand USD | 54.34% |
| 2017 Q3 | 2.16 Million USD | 0.52% |
| 2017 Q1 | 2.12 Million USD | -0.01% |
| 2017 Q2 | 2.14 Million USD | 1.04% |
| 2017 FY | -147.1 Thousand USD | -106.91% |
| 2017 Q4 | -147.1 Thousand USD | -106.81% |
| 2016 Q3 | 2.04 Million USD | -0.31% |
| 2016 Q1 | 1.98 Million USD | 11.69% |
| 2016 Q2 | 2.04 Million USD | 3.48% |
| 2016 Q4 | 2.12 Million USD | 4.15% |
| 2016 FY | 2.12 Million USD | 20.0% |
| 2015 Q3 | 2.08 Million USD | -0.0% |
| 2015 FY | 1.77 Million USD | 1.03% |
| 2015 Q4 | 1.77 Million USD | -14.92% |
| 2015 Q1 | 1.98 Million USD | 12.95% |
| 2015 Q2 | 2.08 Million USD | 5.13% |
| 2014 Q1 | 3.11 Million USD | 0.03% |
| 2014 Q2 | 2.95 Million USD | -5.39% |
| 2014 Q3 | 2.72 Million USD | -7.71% |
| 2014 Q4 | 1.75 Million USD | -35.53% |
| 2014 FY | 1.75 Million USD | -43.69% |
| 2013 Q3 | 3.81 Million USD | 0.76% |
| 2013 Q2 | 3.78 Million USD | 0.87% |
| 2013 Q1 | 3.75 Million USD | 17.65% |
| 2013 FY | 3.11 Million USD | -2.33% |
| 2013 Q4 | 3.11 Million USD | -18.32% |
| 2012 FY | 3.19 Million USD | 135.31% |
| 2012 Q2 | 806.24 Thousand USD | -31.76% |
| 2012 Q3 | 2.11 Million USD | 161.92% |
| 2012 Q4 | 3.19 Million USD | 51.14% |
| 2012 Q1 | 1.18 Million USD | -12.89% |
| 2011 Q2 | 95.41 Thousand USD | -92.73% |
| 2011 FY | 1.35 Million USD | 93.08% |
| 2011 Q4 | 1.35 Million USD | 48.64% |
| 2011 Q3 | 912.5 Thousand USD | 856.32% |
| 2011 Q1 | 1.31 Million USD | 86.79% |
| 2010 FY | 702.5 Thousand USD | 172.59% |
| 2010 Q4 | 702.5 Thousand USD | 391.81% |
| 2010 Q1 | 38.8 Thousand USD | 104.01% |
| 2010 Q2 | -568.32 Thousand USD | -1564.69% |
| 2010 Q3 | 142.84 Thousand USD | 125.13% |
| 2009 Q3 | -1.46 Million USD | -1171.22% |
| 2009 FY | -967.73 Thousand USD | -21.69% |
| 2009 Q4 | -967.73 Thousand USD | 33.89% |
| 2009 Q2 | 136.65 Thousand USD | 136.14% |
| 2009 Q1 | -378.12 Thousand USD | 52.45% |
| 2008 Q3 | -1.03 Million USD | 69.09% |
| 2008 Q4 | -795.22 Thousand USD | 23.47% |
| 2008 Q2 | -3.36 Million USD | 40.87% |
| 2008 Q1 | -5.68 Million USD | -453.01% |
| 2008 FY | -795.22 Thousand USD | -149.38% |
| 2007 FY | 1.61 Million USD | 268.58% |
| 2007 Q4 | 1.61 Million USD | -2.76% |
| 2007 Q2 | 1.57 Million USD | 114.19% |
| 2007 Q3 | 1.65 Million USD | 5.28% |
| 2007 Q1 | 734.46 Thousand USD | 68.1% |
| 2006 Q3 | -592.58 Thousand USD | 72.62% |
| 2006 Q4 | 436.93 Thousand USD | 173.73% |
| 2006 Q2 | -2.16 Million USD | -749.4% |
| 2006 Q1 | 333.31 Thousand USD | 31.29% |
| 2006 FY | 436.93 Thousand USD | 72.1% |
| 2005 Q3 | 317.18 Thousand USD | 41.54% |
| 2005 Q2 | 224.09 Thousand USD | 79.29% |
| 2005 FY | 253.88 Thousand USD | -40.95% |
| 2005 Q1 | 124.99 Thousand USD | -70.93% |
| 2005 Q4 | 253.88 Thousand USD | -19.96% |
| 2004 Q3 | 786.65 Thousand USD | 124.99% |
| 2004 Q1 | 327.21 Thousand USD | -9.89% |
| 2004 FY | 429.95 Thousand USD | 18.41% |
| 2004 Q4 | 429.95 Thousand USD | -45.34% |
| 2004 Q2 | 349.63 Thousand USD | 6.85% |
| 2003 Q1 | 359.4 Thousand USD | 6.08% |
| 2003 Q2 | 306.44 Thousand USD | -14.73% |
| 2003 FY | 363.11 Thousand USD | 101.14% |
| 2003 Q4 | 363.11 Thousand USD | -3.07% |
| 2003 Q3 | 374.6 Thousand USD | 22.24% |
| 2002 Q3 | 201.07 Thousand USD | -34.57% |
| 2002 Q2 | 307.29 Thousand USD | 832.15% |
| 2002 Q1 | -41.97 Thousand USD | -133.23% |
| 2002 FY | -31.8 Million USD | 0.0% |
| 2002 Q4 | 338.78 Thousand USD | 68.49% |
| 2001 Q3 | 210.98 Thousand USD | 31.48% |
| 2001 Q2 | 160.47 Thousand USD | 19.4% |
| 2001 Q4 | 126.31 Thousand USD | -40.13% |
| 2001 Q1 | 134.39 Thousand USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| American Medical Technologies Inc. | 479.63 Thousand USD | 109.029% |
| Ansell Limited | -54.99 Million USD | 99.921% |
| Ansell Limited | -55.1 Million USD | 99.921% |
| BG Medicine, Inc. | - USD | Infinity% |
| Biotage AB (publ) | -36.49 Million USD | 99.881% |
| BioLife Sciences Inc. | - USD | Infinity% |
| CB Scientific, Inc. | -105.1 Thousand USD | 58.798% |
| Psykey, Inc. | 634.59 Thousand USD | 106.824% |
| ConvaTec Group Plc | 1.2 Billion USD | 100.004% |
| ConvaTec Group Plc | 1.2 Billion USD | 100.004% |
| Encision Inc. | 1.29 Million USD | 103.355% |
| Golden Valley Development, Inc | - USD | Infinity% |
| Hear AtLast Holdings, Inc. | 2.3 Million USD | 101.876% |
| Innovative MedTech Inc. | 1.76 Million USD | 102.454% |
| LifePoint, Inc. | -3.26 Million USD | 98.673% |
| Medite Cancer Diagnostics, Inc. | 4.9 Million USD | 100.883% |
| Paradigm Medical Industries, Inc. | 2.16 Million USD | 102.003% |
| QuantRx Biomedical Corporation | - USD | Infinity% |
| Reflect Scientific, Inc. | -1.03 Million USD | 95.817% |
| SmileDirectClub, Inc. | 778.67 Million USD | 100.006% |
| Sector 10, Inc. | 163 Thousand USD | 126.567% |
| Shandong Weigao Group Medical Polymer Company Limited | -417.55 Million USD | 99.99% |
| SheerVision, Inc. | 57.34 Thousand USD | 175.51% |
| United Health Products, Inc. | 660.56 Thousand USD | 106.556% |
| Vasamed, Inc. | 22.12 Thousand USD | 295.751% |
| Wearable Health Solutions, Inc. | 2.63 Million USD | 101.646% |
| Yubo International Biotech Limited | 772.27 Thousand USD | 105.607% |